Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2025-10.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 93

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 94
Role of neutrophil elastase in predicting infection among children with chemotherapy-induced febrile neutropenia

Role of neutrophil elastase in predicting infection among children with chemotherapy-induced febrile neutropenia

Article information

Clin Exp Pediatr. 2025;68(10):801-807
Publication date (electronic) : 2025 June 10
doi : https://doi.org/10.3345/cep.2025.00318
1Department of Pediatrics, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt
2Department of Clinical Pathology, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt
3Egyptian Ministry of Health, Cairo, Egypt
Corresponding author: Esraa Tawfik Allam. Department of Clinical Pathology, National Liver Institute, Menoufia University, Shebin El-kom, Menoufia, 32511, Egypt Email: esraaallam1980@gmail.com
Received 2025 February 5; Revised 2025 April 29; Accepted 2025 May 8.

Abstract

Background

Infection is a significant cause of death following chemotherapy-induced febrile neutropenia (FN). Neutropenia and compromised neutrophil function are the primary reasons for the decreased defense against infections.

Purpose

This study aimed to evaluate the significance of neutrophil elastase (NE) in predicting the outcomes of childhood hematological malignancies with FN.

Methods

The study included 64 patients with FN and 64 healthy children matched for age and sex as controls. The patients were selected from the Hematology and Oncology Unit, Menoufia University, Pediatric Department, and Tanta Oncology Institute. Complete blood counts, C-reactive protein (CRP) levels, NE levels, and blood cultures for bacteria and fungi were performed.

Results

The levels of CRP and NE were increased among children with FN; of them, 21.9% had Gram-negative bacteremia, 17.2% had Gram-positive bacteremia, and 3.1% had Candidemia. NE level was increased in patients with bacterial infections, with a significant positive correlation with duration of FN. NE level had a cutoff of 6.5, with an area under the curve of 0.899, sensitivity of 83.33%, and specificity of 87.50% signifying a higher risk of mortality compared to other variables.

Conclusion

NE levels were elevated in children with FN, suggesting its usefulness for the early detection of infection that could decrease infection-related morbidity and mortality.

Key message

Question: Can neutrophil elastase (NE) levels predict infection— the primary cause of mortality—among children with hematological malignancies and febrile neutropenia (FN)?

Finding: Elevated levels of NE were found in children with chemotherapy-induced FN and a bacterial infection.

Meaning: Increased NE levels and prolonged FN are important factors associated with mortality risk.

Graphical abstract

Introduction

Patients receiving intensive chemotherapy for hematological malignancy face a significant difficulty with febrile neutropenia (FN) [1,2]. Even with antibiotics given during chemotherapy-induced neutropenia and prompt use of broad antimicrobial drugs when FN begins, approximately 35% of individuals with bacterial sepsis do not survive, increasing to 85% for severe sepsis with multiple organ failure [3]. Between 10%–25% of patients experience invasive fungal infections, with mortality rates reaching 30% for Aspergillus infections and up to 96% for cerebral fungal disease [4,5]. If antimicrobial strategies, such as granulocyte transfusions, were started sooner, it could lead to a reduction in mortality rates [6], Scoring systems like the MASCC (multinational association for aupportive care in cancer) or MEWS (modified early warning score) are used to clinically identify high-risk patients [7].

Neutrophil elastase (NE) is a proteolytic enzyme that belongs to the chymotrypsin-like family of serine-proteinases. NE is a protein that consists of 218 amino acids and is found in cytoplasmic azurophilic granules, which have the potential to be discharged during neutrophil degranulation. NE is an inflammatory agent that decreases the rate at which cilia beat, enhances the production of mucus, and causes damage to the airway epithelium [8].

NE breaks down various substances such as elastin, collagen, and fibronectin. NE hydrolysis makes up around 80% of all protease hydrolysis activity in the human body, leading to inflammation, advancing bacterial infections, and excessive mucus secretion. The disease state and severity are reflected by the levels and activity of NE [9]. Despite its connection to multiple illnesses, NE plays a role in cancer [10] and inflammation resistance [11].

Our goal was to assess the importance of NE as a biomarker for detecting outcomes in pediatric hematological cancers, specifically looking at its capability to predict infections in children with chemotherapy-induced FN.

Methods

1. Study design

The study was conducted on 64 FN patients who were selected from the Hematology and Oncology Unit, Menoufia University Hospital, Pediatric Department and Tanta Oncology Institute and 64 healthy children who were matched in terms of age and sex and had no previous medical issues as controls.

2. Ethical approval

The Institutional Review Board of the Menoufia Faculty of Medicine approved the study. Research work was performed in accordance with the Declaration of Helsinki (approval ID: 3/2023 PEDI 17). All patients and their guardians were informed of the benefits and drawbacks of the study before providing their consent.

3. Inclusion criteria

Patients with either one oral temperature exceeding 38.3°C or 2 temperatures more than 38.0°C within 12 hours, each lasting at least 1 hour, and an absolute neutrophil count (ANC) below 1,000/mm3.

Healthy children with matched age and sex who agree to participate with an ANC within normal range.

4. Data gathering

Every patient received a thorough physical and clinical assessment. Tests conducted in the laboratory included a complete blood count, C-reactive protein (CRP), NE, and blood cultures for bacteria and fungi upon admission on the first day of FN. A chest computed tomography (CT) scan was carried out on the fifth day of FN.

5. Study methods

The Sysmex XT 1800, an automated cell counter from Germany, was utilized to analyze complete blood counts. CRP levels were measured. A blood culture was carried out utilizing the BACT/ALERT automated microbial detection system from Biomerieux in France.

The enzyme-linked immunosorbent assay (ELISA) technique measured levels of serum human NE in both patients and controls. A double antibody ELISA test was conducted using commercial kits from Sunred Biological Technology Co., Ltd. in Shanghai, China (Catalogue No. 201-12-0891). Serum samples were collected, spun at 3,000 rpm for 10 minutes, then divided and stored at -20°C for later NE examination.

Each standard well was given an extra 50 μL. The test wells were given an additional 40 μL of the sample. After adding 50 μL of prepared streptavidin-horseradish peroxidase solution to every standard and test well, 10 μL of NE-antibody was added to each well of the microtiter ELISA plate. Afterward, the plates were transferred to an incubator set at 37°C. Subsequently, the plates were subjected to 5 washes using wash buffer. 50 μL of chromogen solution B and chromogen solution A were added to each well, followed by incubation at 37°C for 10 minutes in the dark, resulting in the liquid turning blue. Then, each well had 50 μL of stop solution added. The liquid changed from blue to yellow right away. The absorption level of each colored solution was evaluated at a wavelength of 450 nm using a microplate reader. The linear regression equation for the standard curve was calculated based on the concentrations of the standards. The OD values obtained were used in the regression equation to find out the sample concentration.

6. Statistical analysis

The data gathered were organized and analyzed using IBM SPSS Statistics ver. 23.0 (IBM Co., USA). Quantitative data were represented using mean and standard deviation, while qualitative data were presented as numbers and percentages. Chi-square test was utilized to examine the relationship between 2 quantitative variables. The Fisher exact test was utilized to investigate the relationship between the 2 qualitative variables if any of the expected cells is less than five. The Student t test was utilized to examine the relationship between the 2 normally distributed quantitative variables. Mann-Whitney U test was used to examine the relationship between the 2 not normally distributed quantitative variables. Spearman correlation (r) was used to study the correlation between the 2 not normally distributed quantitative variables. Receiver operator characteristics (ROCs) were created to evaluate biomarker performance by identifying points where sensitivity and specificity are maximized for accuracy. A P value less than 0.05 is considered statistically significant.

Results

Based on demographic and laboratory investigations of the studied groups, there were significant difference between patients and controls regarding hemoglobin concentration, total leukocyte count, ANC, platelet count, CRP, and NE as presented in Table 1.

Demographic characteristics and laboratory investigations by study group

Based on the type of malignancy in neutropenic patients, acute lymphoblastic leukemia pre-B cells were the most common. Categorization of FN into moderate (ANC, 500–1,000/mm3, severe (ANC<500 mm3) and profound (ANC<100 mm3) based on ANC as demonstrated in Table 2.

Type of malignancy and degree of neutropenia among patients with febrile neutropenia (N=64)

Regarding septic focus, 41 patients (64.1%) had no septic focus, 21 patients (32.8%) had pneumonia, 4 patients (6.3%) had oral mucositis, 29 patients (45.3%) got gastroenteritis, and 5 patients (7.8%) had typhlitis. In terms of CT chest findings, 39 patients (61%) had normal CT chest findings, 15 cases (23.4%) showed pneumonia, 5 patients exhibited a ground glass appearance, and 5 had pleural effusion (7.8% each). Klebsiella pneumoniae was the most common bacterial infection (12.5%) following by Staphylococcus aureus (9.4%) and Streptococcus pneumoniae (7.8%). Candidemia account 3.1% of cases according to Table 3.

Septic focus, blood culture results, and chest computed tomography (CT) findings in patients with febrile neutropenia

Based on the blood culture findings, 37 patients had negative results (57.8%). K. pneumoniae was detected in 8 patients, 2 survivors (3.8%) and 6 nonsurvivors (54.5%) with a statistically significant difference (P<0.001). Pseudomonas aeruginosa was found in 2 nonsurvivors (18.2%), showing a statistically significant difference (P=0.027). There were 2 nonsurvivors (18.2%) with Candida, showing a statistically significant difference (P=0.273). Gram-positive bacteremia (17.2%) was observed in 9 survivors (17%) and 2 nonsurvivors (18.2%) and Gram-negative bacteremia (21.9%) was observed in 6 survivors (11.3%) and 8 nonsurvivors (72.7%) with a P value of 0.003 as indicated in Table 4.

Blood culture results and bacteremia type survivors versus nonsurvivors

Table 5 displayed a notable increase in NE and CRP levels among patients with bacterial infection compared to those without it, with statistical significant difference at (P<0.001 and P=0.001, respectively).

CRP and NE levels of cases with versus without bacterial infections

Fig. 1 illustrates a significant positive association between NE and the length of FN (r=0.6, P<0.001). Fig. 2 illustrates the analysis of the ROC curve of NE and CRP to predict infections in patients with FN revealed a cutoff point of 6.5, with an area under the curve (AUC) of 0.899, a sensitivity of 83.33%, and a specificity of 87.50%. CRP revealed a cutoff point of 6.1, with an AUC of 0.9, a sensitivity of 81.3%, and a specificity of 99.5%.

Fig. 1.

Correlation between neutrophil elastase level and duration of febrile neutropenia.

Fig. 2.

Receiver operating characteristic (ROC) curve analysis of ability of neutrophil elastase and C-reactive protein (CRP) levels to predict bacterial infections among patients with febrile neutropenia.

Factors that increase the risk of mortality in cases with FN included NE (P=0.002), duration of FN (P=0.003), bacterial growth (P=0.01) and CRP (P=0.025) as shown in Table 6.

Risk factors associated with mortality in patients with febrile neutropenia

Discussion

Infections pose a significant risk of morbidity and mortality for children with cancer who are undergoing chemotherapy or receiving a transplant. Neutropenia is a serious risk of cancer therapy and increases the chance of bacterial infections which can be life-threatening [12].

The current study demonstrated higher levels of CRP and NE in children with cancer who developed FN due to chemotherapy. During neutropenic episodes, the acute myeloid leukemia patients experienced increased levels of CRP and NE as reported by Van de Geer et al. [13].

The most frequent bacterial infection was K. pneumoniae (12.5%), with S. aureus (9.4%) and S. pneumoniae (7.8%). Gram-negative bacteremia occurred in 21.9% of cases, while Gram-positive bacteremia occurred in 17.2%. Candidemia occurred in 3.1% of cases. Antari et al. [14] reported that 19% of cases of FN were caused by Gram-negative bacteria, with Gram-positive bacteria and Candidemia each accounting for 3% of cases. Gram-negative bacteria that were found were P. aeruginosa, E. coli, and Klebsiella. Van de Geer et al. [13] discovered that bacterial infection occurred in 34.6% of neutropenic episodes, while fungal infection occurred in 7.7%.

Levels of NE were elevated in patients with bacterial infection with a highly significant positive correlation with the duration of FN. NE had a cutoff of 6.5, with an AUC of 0.899, a sensitivity of 83.33%, and a specificity of 87.50% indicating higher mortality risk compared to other variables. CRP revealed a cutoff point of 6.1, with an AUC of 0.9, a sensitivity of 81.3%, and a specificity of 99.5%. NE is more sensitive than CRP indicating that it is increased in true positive cases.

An increase in NE levels was linked to neutrophil regeneration prior to the detection of circulating neutrophils. Comparing the hazard ratio for NE levels above versus below the median concentration, the value was 6.3 (95% confidence interval, 2.6–15.2; P<0.001). This discovery is beneficial for patients with refractory infections and prolonged neutropenia. When deciding on whether intensifying treatment is necessary during prolonged neutropenia, including the use of granulocyte transfusions, it is reassuring to have the ability to anticipate autologous neutrophil recovery for fighting severe infections [6].

CRP seems to provide less useful information. This could be because every neutropenic patient shows increased CRP levels, which may be caused by the inflammatory impact of their primary illness, previous chemotherapy, and/or therapy-related mucosal injuries [15-18].

Mean CRP peak level was reached at 36–48 hours in children with cancer after the start of infection. CRP showed a slower kinetics, this slow kinetic may lead to false negative results [19].

The measurement of human NE-like activity was conducted in cell lysates from isolated peripheral polymorphonuclear neutrophils, demonstrating repeatable and reliable results for up to 26 hours. Consequently, its highest level could persist for as long as 26 hours [20]. So, the NE kinetics may be faster and favorable than that of CRP.

Few studies have examined the kinetics of CRP, procalcitonin (PCT), and interleukin-6 (IL-6) in pediatric patients with fever and neutropenia. De Lucio Delgado et al. [19] illustrated that IL-6 demonstrated the fastest kinetics, then PCT. The highest level of IL-6 was achieved in the initial blood sample after the onset of the fever episode. PCT and IL-6 proved to be more reliable indicators than CRP for predicting bacteremia in individuals with FN [21].

De Lucio Delgado et al. [19] illustrated the ability of plasma interleukin-8 (IL-8) levels measured 24–48 hours prior to diagnosis to distinguish between patients with FN due to bloodstream infections and those with FN resulting from other causes. Many studies have shown that IL-8 concentrations are elevated in patients with bacterial infections during neutropenia, whereas CRP appears to be less effective [15,22].

Also, patients suffering from bacterial pneumonia show elevated NE levels in bronchoalveolar lavage fluid, leading to excessive proteolytic damage and worse clinical outcomes [23,24].

The limitation of this study was small number of patients. The strength of this study was uniquely evaluated NE as a promising biomarker to identify bacterial exacerbation in children with chemotherapy-induced FN and it is the first study investigating NE in many types of childhood malignancy with chemotherapy-induced FN and its role in prediction of FN.

In conclusion, NE levels were elevated in children with FN promising for early detection of infection to decrease infection-related morbidity and mortality.

Notes

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Acknowledgments

The authors are thankful to both the individuals involved in the study and the team who collected the data.

Author Contribution

Conceptualization: ME, DE, MA, EA, MK, AM; Formal analysis, ME, DE, MA, EA, MK, AM; Funding acquisition, ME, DE, MA, EA, MK, AM; Investigation: ME, DE, MA, EA, MK, AM; Methodology: ME, DE, MA, EA, MK, AM; Writing, review, and editing: ME.

References

1. Weycker D, Barron R, Kartashov A, Legg J, Lyman GH. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract 2014;20:190–8.
2. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2013;31:794–810.
3. Azoulay E, Mokart D, Pène F, Lambert J, Kouatchet A, Mayaux J, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium-A groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol 2013;31:2810–8.
4. Pagano L, Busca A, Candoni A, Cattaneo C, Cesaro S, Fanci R, et al. Risk for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev 2017;31:17–29.
5. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634–53.
6. Netelenbos T, Massey E, de Wreede LC, Harding K, Hamblin A, Sekhar M, et al. The burden of invasive infections in neutropenic patients: incidence, outcomes, and use of granulocyte transfusions. Transfusion 2019;59:160–8.
7. Combariza JF, Lombana M, Pino LE, Arango M. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms. Support Care Cancer 2015;23:1009–13.
8. Roghanian A, Drost EM, MacNee W, Howie SE, Sallenave JM. Inflammatory lung secretions inhibit dendritic cell maturation and function via neutrophil elastase. Am J Respir Crit Care Med 2006;174:1189–98.
9. Voynow JA, Shinbashi M. Neutrophil elastase and chronic lung disease. Biomolecules 2021;11:1065.
10. Cui C, Chakraborty K, Tang XA, Zhou G, Schoenfelt KQ, Becker KM, et al. Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell 2021;184:3163–77.e21.
11. Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol 2010;10:712–23.
12. Boeriu E, Borda A, Vulcanescu DD, Sarbu V, Arghirescu ST, Ciorica O, et al. Diagnosis and management of febrile neutropenia in pediatric oncology patients-a systematic review. Diagnostics (Basel) 2022;12:1800.
13. van de Geer A, Zandstra J, Tanck MW, Nur E, van Mierlo G, Jongerius I, et al. Biomarkers to predict infection and infection-related complications during chemotherapy-induced neutropenia in acute myeloid leukemia: a pilot study. Br J Haematol 2021;193:1008–12.
14. Antari V, Skoura L, Hatzipantelis E, Tsinopoulou VR, Papakonstantinou K, Protonotariou E, et al. Kinetics and role of pancreatic stone protein and midregional proadrenomedullin as predictors of sepsis and bacteremia in children with hematological malignancies. Mediterr J Hematol Infect Dis 2023;15e2023065.
15. Miedema KG, Vermont CL, Ball LM, de Bont ES, Kamps WA, van Tol MJ, et al. The diagnostic value of interleukin-8 for the detection of bacteremia in pediatric hematopoietic stem cell recipients with febrile neutropenia. Transplantation 2014;98:e80–1.
16. Ebihara Y, Kobayashi K, Ishida A, Maeda T, Takahashi N, Taji Y, et al. Diagnostic performance of procalcitonin, presepsin, and C-reactive protein in patients with hematological malignancies. J Clin Lab Anal 2017;31e22147.
17. Binder S, Luciano M, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators. Cytokine Growth Factor Rev 2018;43:8–15.
18. Landry A, Docherty P, Ouellette S, Cartier LJ. Causes and outcomes of markedly elevated C-reactive protein levels. Can Fam Physician 2017;63:e316–23.
19. De Lucio Delgado A, Villegas Rubio JA, Rey Galán C, Prieto García B, González Expósito ML, Solís Sánchez G. Biomarkers and fever in children with cancer: kinetics and levels according to final diagnosis. Children (Basel) 2021;8:1027.
20. Birk D, Siepmann E, Simon S, Sommerhoff CP. Human neutrophil elastase: characterization of intra- vs. extracellular inhibition. Int J Mol Sci 2024;25:7917.
21. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: Procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 2004;23:539–44.
22. Michel CS, Teschner D, Wagner EM, Theobald M, Radsak MP. Diagnostic value of sTREM-1, IL-8, PCT, and CRP in febrile neutropenia after autologous stem cell transplantation. Ann Hematol 2017;96:2095–101.
23. Wilkinson TS, Conway Morris A, Kefala K, O'Kane CM, Moore NR, Booth NA, et al. Ventilator-associated pneumonia is characterized by excessive release of neutrophil proteases in the lung. Chest 2012;142:1425–32.
24. Grunwell JR, Giacalone VD, Stephenson S, Margaroli C, Dobosh BS, Brown MR, et al. Neutrophil dysfunction in the airways of children with acute respiratory failure due to lower respiratory tract viral and bacterial coinfections. Sci Rep 2019;9:2874.

Article information Continued

Fig. 1.

Correlation between neutrophil elastase level and duration of febrile neutropenia.

Fig. 2.

Receiver operating characteristic (ROC) curve analysis of ability of neutrophil elastase and C-reactive protein (CRP) levels to predict bacterial infections among patients with febrile neutropenia.

Table 1.

Demographic characteristics and laboratory investigations by study group

Variable Febrile neutropenia patients (n=64) Controls (n=64) Test of significance P value
Sex, n (%) 9.051a) 0.003
 Male 39 (60.9) 22 (34.4)
 Female 25 (39.1) 42 (65.6)
Age (yr) 0.67b) 0.498
 Mean±SD 8.63±5.17 9.32±5.25
 Median (range) 7 (2–17) 9 (1–17)
Hb (g/dL) 7.14c) <0.001
 Mean±SD 9.54±1.55 11.24±1.09
 Median (range) 9.4 (5.5–12.9) 11.0 (10.5–13.8)
TLC (/mm3) 9.48b) <0.001
 Mean±SD 4.23±3.1 9.6±5.7
 Median (range) 4 (1–5) 6 (4–10)
ANC (/mm3) 9.76b) <0.001
 Mean±SD 156.4±132.5 2,122.9±590.6
 Median (range) 110 (20–550) 2,129.5 (1,500.0–3,420.0)
Platelet count (/mm3) 7.29b) <0.001
 Mean±SD 83.64±8.39 217±37.1
 Median (range) 50 (9–179) 207.5 (165.0–295.0)
CRP (mg/dL) 9.58b) <0.001
 Mean±SD 114.1±112.9 3.11±1.31
 Median (range) 96 (0–384) 0 (0–12)
NE (ng/mL) 6.47b) <0.001
 Mean±SD 220. 4±214.1 77.5±44.7
 Median (range) 146.7 (27.8–854.0) 64.07 (18.98–203.17)

SD, standard deviation; Hb, bemoblobin; TLC, total leukocyte count; ANC, absolute neutrophil count; CRP, C-reactive protein; NE, neutrophil elastase.

a)

Chi-square test.

b)

Mann-Whitney U test.

c)

Student t test.

ldface indicates a statistically significant difference with P<0.05.

Table 2.

Type of malignancy and degree of neutropenia among patients with febrile neutropenia (N=64)

Type of malignancy No. (%)
ALL (pre-B cell) 28 (43.8)
ALL (T cell) 13 (20.3)
T-lymphoblastic non-Hodgkin lymphoma 9 (14.0)
AML 7 (10.9)
Burkitt lymphoma 3 (4.7)
Hodgkin lymphoma 4 (6.3)
Degree of neutropenia
 Moderate 3 (4.7)
 Severe 39 (60.9)
 Profound 22 (34.4)

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia.

Table 3.

Septic focus, blood culture results, and chest computed tomography (CT) findings in patients with febrile neutropenia

Studied variables No. (%)
Septic focus
 No septic focus 41 (64.1)
 Pneumonia 21 (32.8)
 Oral mucositis 4 (6.3)
 Gastroenteritis 29 (45.3)
 Typhlitis 5 (7.8)
CT chest findings
 Pneumonia 15 (23.4)
 Ground glass appearance 5 (7.8)
 Pleural effusion 5 (7.8)
 No septic focus 39 (61)
Blood culture results
E. coli 2 (3.1)
K. pneumonia 8 (12.5)
P. aeruginosa 2 (3.1)
Candida 2 (3.1)
Acinetobacter 2 (3.1)
Staphylococcus aureus 6 (9.4)
Streptococcus 5 (7.8)
 No growth 37 (57.8)

Values are presented as number (%).

Table 4.

Blood culture results and bacteremia type survivors versus nonsurvivors

Blood culture Survivors (n=53) Nonsurvivors (n=11) Testa) P value
E.coli 2 (3.8) 0 (0) 0.43 1
K. pneumonia 2 (3.8) 6 (54.5) 21.47 <0.001
P. aeruginosa 0 (0) 2 (18.2) 9.95 0.027
Candida 0 (0) 2 (18.2) 9.95 0.027
S. aureus 4 (7.5) 2 (18.2) 1.21 0.273
Acinetobacter 2 (3.8) 0 (0) 0.43 1.000
Streptococcus 5 (9.4) 0 (0) 1.13 0.578
Type of bacteremia 11.89b) 0.003
 Gram-positive bacteremia 9 (17.0) 2 (18.2)
 Gram-negative bacteremia 6 (11.3) 8 (72.7)

Values are presented as number (%).

a)

Fisher exact test.

b)

Chi-square test.

Boldface indicates a statistically significant difference with P<0.05.

Table 5.

CRP and NE levels of cases with versus without bacterial infections

Variable Cases with bacterial infection (n=27) Cases without bacterial infection (n=37) Testa) P value
CRP (mg/dL) 3.22 0.001
 Mean±SD 175.0±139.3 75.8±56.2
 Median (range) 192 (12–384) 24 (0–192)
NE (ng/mL) 7.29 <0.001
 Mean±SD 323.2±306.6 158.9±90.8
 Median (range) 253.80 (98.89–854.00) 126.10 (49.24–208.44)

CRP, C-reactive protein; NE, neutrophil elastase; SD, standard deviation.

a)

Mann-Whitney U test.

Boldface indicates a statistically significant difference with P<0.05.

Table 6.

Risk factors associated with mortality in patients with febrile neutropenia

Variables Survivors (N=53) Nonsurvivors (N=11) Test P value
Age (yr) 0.46a) 0.64
 Mean±SD 8.47±5.12 9.41±5.63
 Median (range) 7 (2–18) 8 (2.5–17)
Sex, n (%) 0.93b) 0.74
 Male 33 (62.3) 6 (54.6)
 Female 20 (37.7) 5 (45.5)
Diagnosis, n (%) 8.0c) 0.33
 ALL (pre-B cell) 26 (49) 2 (18.2)
 ALL (T cell) 10 (18.9) 3 (27.3)
 AML 3 (5.7) 4 (36.4)
 T-lymphoblastic non-Hodgkin lymphoma 7 (13.2) 2 (18.2)
 Burkitt's lymphoma 3 (5.7) 0 (0.0)
 Hodgkin's lymphoma 4 (7.5) 0 (0.0)
CRP (mg/dL) 2.24a) 0.025
 Mean±SD 92.72±94.30 210.55±152.08
 Median (range) 48 (0–384) 192 (6–384)
NE (ng/mL) 3.17a) 0.002
 Mean±SD 176.47±159.72 432.56±310.56
 Median (range) 139.89 (27.89–854.00) 293.78 (49.24–837.33)
Duration of fever neutropenia (day) 2.96a) 0.003
 Mean±SD 1.70±0.91 3.0±1.34
 Median (range) 1 (1–4) 4 (1–4)
Bacterial growth 7.81b) 0.01
 No growth 38 (71.7) 1 (9.1)
 Bacterial growth 15 (28.3) 10 (90.9)
Duration of hospital stay (day) 0.34a) 0.73
 Mean±SD 18.75±6.67 19.45±9.33
 Median (range) 20 (5–32) 20 (5–32)

SD, standard deviation; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CRP, C-reactive protein; NE, neutrophile elastase.

a)

Mann-Whitney U test.

b)

Fisher exact test.

b)

Chi-square test.

Boldface indicates a statistically significant difference with P<0.05.